4 min read
Plenary Session Presentation: Putting Science First in Rare Disease Studies
Don´t miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Boston, Thursday, April 25th at...
1 min read
Veristat, a full service Clinical Research Organization (CRO), announced today the signing of a Preferred Provider Agreement (PPA) with Aegerion Pharmaceuticals Inc. (“Aegerion”), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Veristat has assisted Aegerion with US Food and Drug Administration, EU Market Authorization Application, and Japan Food and Drug Administration submission projects over the past 5 years.
Veristat will offer Aegerion clinical trial support including statistical consulting, biostatistical analysis, clinical data management, clinical monitoring, SAS programming, clinical protocol and study report writing, project management and the preparation of regulatory submission documents.
“Veristat has been a strong and dedicated collaborative partner and an extension of our project teams,” said Pamela Foulds, MD, Vice President of Clinical Development at Aegerion Pharmaceuticals.
“Veristat is thrilled to progress to this next phase in our working relationship with Aegerion,” stated Barbara Balser, VMD, Chief Scientific Officer at Veristat. “We feel like a true partner to Aegerion and are eager to continue to deliver quality expertise and services for their marketing applications.”
4 min read
Mar 22, 2024 Veristat Events
Don´t miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Boston, Thursday, April 25th at...
1 min read
Mar 19, 2024 Veristat Events
Meet Veristat in Basel at the Swiss Biotech Day, 22-23 April 2024
With nearly 30 years of experience in clinical trial...